GleamWall
中文EN

NKTR NEKTAR THERAPEUTICS

Pharmaceutical Preparations · Nasdaq · SEC CIK 906709 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-16.6%
TTM net income YoY-46.8%
TTM EPS YoY18.0%
Revenue 3-yr CAGR-16.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-319.8%
Net margin-339.7%
FCF margin-493.4%
EBITDA margin-318.5%

Returns

ROE-37.9%
ROA-26.5%
ROIC (approx.)-30.7%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets18.1%
Debt / equity0.00x
Current ratio9.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.45x
Accruals ratio11.9%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.39M$10.13M$10.86M$21.81M$11.79M$11.18M$10.46M$29.18M
Cost of revenue———$0$0$0$0$7.98M
Gross profit———$21.81M$11.79M$11.18M$10.46M$21.20M
R&D expense$44.12M$39.13M$35.68M$29.71M$27.25M$29.89M$30.48M$28.75M
SG&A expense$24.57M$12.77M$13.44M$11.19M$16.07M$17.07M$24.35M$17.14M
Operating income-$57.80M-$42.34M-$39.05M-$27.66M-$31.67M-$36.23M-$44.53M$14.35M
Pretax income-$55.05M-$40.30M-$43.09M-$43.43M-$35.02M-$39.40M-$46.37M$7.00M
Income tax$22,000$2,000$64,000$31,000-$33,000-$188,000$52,000-$259,000
Net income-$55.65M-$40.62M-$44.90M-$36.08M-$35.52M-$41.59M-$50.88M$7.26M
EBITDA-$57.63M-$42.19M-$38.90M-$27.48M-$31.48M-$36.02M-$44.11M$14.39M
EPS (basic)-1.63-1.23-1.82—-1.87-2.95-3.62—
EPS (diluted)-1.63-1.23-1.82—-1.87-2.95-3.62—
Weighted avg. shares (diluted)34.18M33.05M24.74M—18.95M14.09M14.06M—
Balance sheet
Cash & equivalents$34.69M$39.27M$149.58M$15.12M$41.03M$42.99M$38.89M$44.25M
Short-term investments$579.67M$645.07M$419.03M$230.64M$229.18M$132.91M$179.74M$210.97M
Receivables———————$0
Inventory———$0———$0
Current assets$679.33M$739.40M$589.04M$266.27M$281.36M$186.57M$229.91M$261.29M
PP&E, net———$2.06M$2.83M$2.99M$3.16M$3.41M
Total assets$1.04B$1.10B$763.27M$280.41M$301.35M$207.53M$256.24M$303.85M
Current liabilities$75.48M$70.98M$57.71M$53.54M$66.34M$71.39M$70.93M$61.40M
Total liabilities$187.53M$192.01M$187.06M$190.57M$216.26M$231.75M$242.50M$243.11M
Shareholders' equity$849.72M$903.12M$576.22M$89.83M$85.09M-$24.21M$13.74M$60.74M
Shares outstanding34.21M20.38M20.38M20.38M19.65M12.46M186.10M12.39M
Cash flow statement
Operating cash flow-$71.93M-$75.77M-$44.30M-$64.96M-$48.76M-$45.74M-$49.05M-$46.19M
Capital expenditure$398,000$94,000$18,000$18,000$114,000$37,000$2,000$459,000
Free cash flow-$72.33M-$75.86M-$44.32M-$64.98M-$48.88M-$45.77M-$49.05M-$46.65M
Investing cash flow$66.90M-$399.11M-$350.79M$372,000-$94.87M$49.62M$43.69M$60.21M
Financing cash flow$448,000$364.57M$529.55M$38.67M$141.68M$211,000$7,000$83,000
Depreciation & amortization$169,000$156,000$151,000$190,000$196,000$214,000$426,000$41,000
Stock-based compensation$3.75M$3.37M$3.35M$2.19M$3.07M$3.49M$3.90M$4.80M
Share buybacks———$0$0$0$0$0

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.